Zepbound vs Ozempic: FDA Indications and Trial Findings

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

The PlexusDx Education Hub tracks FDA indications, GLP-1 trial findings, tolerability, and the genetics behind each metabolic decision. Browse all Peptides & GLP-1 education

This comparison is editorially independent. PlexusDx has no commercial relationship with the manufacturers of the products reviewed.

For readers who care first about what each drug is cleared to treat, Zepbound and Ozempic are most clearly compared through the lens of their FDA labels. Regulatory scope, not marketing, determines how each is prescribed and paid for. This overview, current as of April 2026, opens with indications, then works through molecule design, trial findings, tolerability, cost, and genetics.

Where each drug is FDA-cleared

The indications set the frame. Zepbound (tirzepatide) is FDA-approved for chronic weight management (2023) and, since 2024, for moderate-to-severe obstructive sleep apnea in adults with obesity. Ozempic (semaglutide) is FDA-approved for type 2 diabetes (2017). For context across the field, Rybelsus covers oral diabetes (2019), Wegovy weight management (2021), Mounjaro diabetes (2022), Trulicity diabetes (2014), and Victoza diabetes (2010); retatrutide remains investigational.

Molecule design: dual versus single

Behind the labels sit two different molecules. Tirzepatide is a GIP and GLP-1 dual receptor agonist; semaglutide is a selective GLP-1 receptor agonist. Both act at the GLP-1 receptor to slow gastric emptying, blunt post-meal glucose, and increase satiety, but only tirzepatide adds GIP-receptor activity. That second incretin arm is the core design difference separating Zepbound from Ozempic.

Trial findings side by side

The evidence sorts by program. Zepbound draws on SURMOUNT (weight management) and SURMOUNT-OSA (sleep apnea); Ozempic draws on SUSTAIN and SELECT (glycemic and cardiovascular outcomes). Direct comparison exists where tested — SURPASS-2 pitted tirzepatide against semaglutide 1 mg in type 2 diabetes. Populations and endpoints differ across these trials, so findings are most reliable read individually rather than pooled into a single verdict.

Tolerability and boxed warnings

Tolerability is broadly a class trait. Both molecules carry the boxed warning for thyroid C-cell tumor risk observed in rodent studies and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Gastrointestinal effects — nausea, vomiting, diarrhea, constipation — are most common and typically peak during escalation; rare serious events include pancreatitis and gallbladder disease.

Pricing and access notes

Access follows the label. As of April 2026, list prices for the FDA-approved brands range roughly $815 to $1,620 per month at U.S. list price (manufacturer published pricing). Out-of-pocket cost depends on insurance coverage, the indication on the prescription, savings-card eligibility, and whether a compounded alternative is available through a licensed compounding pathway.

Genetics beneath the incretin response

Beneath every indication and molecule lies inherited biology. Variants in FTO (fat-mass and obesity-associated), GLP1R (encoding the GLP-1 receptor), MC4R (central to energy balance), and TCF7L2 (linked to glucose homeostasis and GLP-1 secretion) shape the metabolic terrain any incretin compound works within. These pathway-level markers do not predict response to semaglutide or tirzepatide, but they describe the biology a clinician prescribes into.

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. Before any GLP-1 pathway protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights — including FTO, GLP1R, MC4R, and TCF7L2 variants that shape your baseline biology. That is the test before you invest approach.

Related reading on PlexusDx: Ozempic What is It, Injection Sites for Ozempic, Ozempic Price with Insurance, GoodRx Coupon for Ozempic.

Disclaimer: This article is educational. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols and covers the mechanism, evidence, and genetic context that inform any decision to use them. PlexusDx does not sell, prescribe, or recommend any other GLP-1-category peptide beyond semaglutide and tirzepatide (including dulaglutide, liraglutide, retatrutide, cagrilintide, and related compounds). The Precision Peptide Genetic Test analyzes how your genes influence peptide-related pathways; it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Start with the biology. Take the Precision Peptide Genetic Test, or explore the Weight Management Protocols.

Frequently Asked Questions

What is each drug FDA-approved to treat?

Zepbound (tirzepatide) is approved for chronic weight management and, since 2024, obstructive sleep apnea in adults with obesity. Ozempic (semaglutide) is approved for type 2 diabetes. The indication a prescription is written under shapes both prescribing and insurance coverage for either medication.

Do the trial findings favor one drug?

They are most reliably read per-trial. SURPASS-2 showed larger mean weight reduction with tirzepatide versus semaglutide 1 mg in type 2 diabetes, but Zepbound and Ozempic were studied in different programs and populations against different endpoints. Individual response varies, so discuss the evidence with a provider.

Are the tolerability profiles different?

They are broadly similar across the class. Gastrointestinal effects are most common and typically peak during dose escalation, and both carry the boxed warning for thyroid C-cell tumor risk seen in rodent studies. Rare serious events include pancreatitis and gallbladder disease — review your full history with a provider.

Does the genetic test predict which drug fits my labels?

No. The Precision Peptide Genetic Test analyzes pathway-level variants in FTO, GLP1R, MC4R, and TCF7L2 that describe baseline GLP-1 biology. It is educational context that applies regardless of indication or molecule, not a predictor of response to semaglutide, tirzepatide, or any medication.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.